Celcuity Inc. (CELC)
CELCNASDAQ-CMMedical Specialities
$67.05
-3.32 (-4.72%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $3.29bn
- P/E
- –
- EPS, last 4 quarters
- $-4.71
- Dividend yield
- –
- Day range
- –
- 52-week range
- $53.54 to $151.02
- Average volume
- 1.32m
- Previous close
- $70.37
Analysts
10 coveringBuy10 buy, 0 hold, 0 sell
Targets a year out average $150.82, +124.9% from here
Earnings
next estimate $-0.9800Next report
Dec 2025
+8.5%
Mar 2026
+9.3%
Jun 2026
-33.3%
Sep 2026
+9.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$49.20m | -$50.51m | -$66.12m | -$77.32m |
| Net income | -$50.97m | -$52.84m | -$78.86m | -$73.34m |
News
8 latest- FDA Accepts Celcuity's REVTORPYK Application; Decision Expected In June 2027; Stock Up RTTNews · 1 day ago
- Celcuity (CELC) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- Celcuity Inc. Reports Third Quarter 2026 Financial Results and Commercial Launch of REVTORPYKFintel · 5 days ago
- What Celcuity (CELC) Said on Its Q3 Earnings CallMarketBeat · 5 days ago
- Cantor Fitzgerald Initiates Coverage of Celcuity with Overweight RatingFintel · Oct 22, 2026
- New Strong Sell Stocks for October 14thZacks · Oct 14, 2026
- Why Celcuity Stock Was a Winner on WednesdayThe Motley Fool · Sep 30, 2026
- Celcuity Submits SNDA To FDA For REVTORPYK In Advanced Breast Cancer RTTNews · Aug 26, 2026
The company
Celcuity is a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. Celcuity's first FDA-approved product is REVTORPYK (gedatolisib), a potent pan-PI3K and mTORC1/2 inhibitor that comprehensively blocks the PI3K/AKT/mTOR (PAM) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K, AKT or mTORC1, alone or together. Celcuity's Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib plus fulvestrant with or without palbociclib in patients with HR+/HER2- ABC, supported FDA approval of REVTORPYK for use in adult patients without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of the VIKTORIA-1 clinical trial have been released.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- celcuity.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.